INO: Summary for INOVIO BIOMED CORP - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Monday, November 23, 2009, 7:49am EST - Canadian Markets open in 1 hour and 41 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Inovio Biomedical Corp. (INO)

On Nov 20: 1.5301 USD 0.00 (0.00%)

MORE ON INO

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

INOVIO BIOMED CORP (AMEX:INO) Delayed quote data

Last Trade:	1.5301 USD
Trade Time:	Nov 20
Change:	0.00 (0.00%)
Prev Close:	1.5301
Open:	N/A
Bid:	N/A
Ask:	N/A
1y Target Est:	3.83

Day's Range:	N/A - N/A
52wk Range:	0.17 - 3.40
Volume:	0
Avg Vol (3m):	1,719,630
Market Cap:	156.03M
P/E (ttm):	N/A
EPS (ttm):	-0.47
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Free Annual Reports

Add INO to Portfolio

Download Data

HEADLINES

•	Biotech Stocks: Inovio, Merck gain; Novavax falls
	at MarketWatch (Fri, Nov 20)

•	DryShips, Synovus: Late Volume Plays
	at TheStreet.com (Fri, Nov 20)

•	NYSSA Presents 13th Annual Biotech and Specialty Pharmaceuticals Conference
	Business Wire (Fri, Nov 20)

•	Emerging Stock Report Initiates Independent Research Coverage on Inovio Biomed Corp
	GlobeNewswire (Fri, Nov 20)

•	Biotech Stocks: Inovio soars, Novavax falls in early action
	at MarketWatch (Fri, Nov 20)

•	Inovio Biomedical Universal Flu Vaccines Demonstrate Broadly Protective Immune Responses Against Multiple Seasonal & Pandemic Influenza Viruses in Pre
	Business Wire (Fri, Nov 20)

•	INOVIO BIOMEDICAL CORP Files SEC form 8-K/A, Change in Directors or Principal Officers
	EDGAR Online (Thu, Nov 19)

•	INOVIO BIOMEDICAL CORP Financials
	EDGAR Online Financials (Thu, Nov 19)

•	Inovio Biomedical Universal DNA Vaccine for Chikungunya Virus Demonstrates Protective Antibody Responses in Monkey Model
	Business Wire (Wed, Nov 18)

•	New Star Analyst Rankings for INOVIO BIOMED CORP
	StarMine (Tue, Nov 17)

More Headlines for INO...

ANALYST

EPS Est (next year) (Dec-07) :	N/A
EPS Est (in 2 years) (Dec-08) :	N/A
Avg Rec (current)*:	2.0
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Inovio Biomedical Corporation, a biomedical company, focuses on developing multiple DNA-based immunotherapies and commercializing its Selective Electrochemical Tumor Ablation (SECTA) therapy.

Full Company Profile

Add to Portfolio

Email to a Friend

•